中文(简体)
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Effects of Peas on Blood Glucose Control

只有注册用户可以翻译文章
登陆注册
链接已保存到剪贴板
状态主动,不招募
赞助商
St. Boniface General Hospital Research Centre
合作者
Agriculture and Agri-Food Canada

关键词

抽象

Diabetes is one of the most common chronic diseases affecting Canadians (PHAC, 2011). Lifestyle modifications that include a diet high in fibre may lower the risk of developing type 2 diabetes (CDA, 2013). In this context, the presence of fibre in carbohydrate rich foods has been widely recognized for its effect on post-prandial glucose response (PPGR). Peas are high in fibre and protein and show great potential as a functional food. A health claim for PPGR would increase market demand for peas, and help those who want to limit the rise in blood sugar after a meal choose products to meet their goals, but there are several gaps in the literature that need to be filled before a submission to Health Canada can be successful: 1) test foods in appropriate serving sizes; 2) test both the glucose and insulin response; 3) test varieties of peas that that currently available on the market; 4) test whole/split peas (not fractions or isolates); 5) compare peas to appropriate starchy reference food (rice or potato). The proposed study design will address all of these gaps in the current literature and take into consideration Health Canada's guidance document for health claims related to the reduction in PPGR, which sets out the criteria by which the validity of such claims will be assessed.
Specific objectives
1. To determine the effect of 3 common market classes of peas on PPGR and insulin response in a cross-over, randomized, controlled clinical trial.
2. To assess the effect of 3 common market classes of peas on appetite-related sensations using visual analog scales.
3. To demonstrate whether the test and reference products were liked or disliked similarly by participants.
4. To assess any gastrointestinal side effects from eating the test products

描述

A randomized, controlled, cross-over study designed to examine the PPGR to peas will be conducted at the I.H. Asper Clinical Research Institute in Winnipeg, Manitoba. The study will be divided into 2 groups of 24 healthy volunteers each. In Group 1, eligible participants who have provided consent will be asked to attend 6 clinic visits in a fasted state. Participants will be given white bread at their first and last visits, peas with rice at 3 visits and rice at 1 visit. At each visit participants will provide 7 blood samples via finger poke, 6 questionnaires about their appetite and a questionnaire about the acceptability of the test food. Each visit will last approximately 2.5h and be separated by 3-10 days. Group 2 will undergo the exact same study procedures as group 1, but rice will be replaced with potato.

日期

最后验证: 08/31/2019
首次提交: 07/26/2015
提交的预估入学人数: 09/15/2015
首次发布: 09/16/2015
上次提交的更新: 09/23/2019
最近更新发布: 09/24/2019
实际学习开始日期: 10/15/2015
预计主要完成日期: 08/13/2017
预计完成日期: 02/29/2020

状况或疾病

Post-prandial Glucose Response

干预/治疗

Other: Group1

Other: Group2

-

手臂组

干预/治疗
Placebo Comparator: White bread 1
Groups 1 and 2, Visit 1 White bread (equal to 50g available carbohydrate) given to fasting participant
Experimental: Pea variety 1 with rice
Group 1,Visit 2-5 Pea variety 1 with rice (25g available carbohydrate of each) given as breakfast to fasting participants
Experimental: Pea variety 2 with rice
Group 1, Visit 2-5 Pea variety 2 with rice (25g available carbohydrate of each) given as breakfast to fasting participants
Experimental: Pea variety 3 with rice
Group 1, Visit 2-5 Pea variety 3 with rice (25g available carbohydrate of each) given as breakfast to fasting participants
Experimental: Rice
Group 1, Visit 2-5 Rice (equal to 50g available carbohydrate) given as breakfast to fasting participants
Placebo Comparator: White bread 2
Groups 1 and 2, Visit 6 White bread (equal to 50g available carbohydrate) given to fasting participant
Experimental: Pea variety 1 with potato
Group 2, Visit 2-5 Pea variety 1 with potato (25g available carbohydrate of each) given as breakfast to fasting participants
Experimental: Pea variety 2 with potato
Group 2, Visit 2-5 Pea variety 2 with potato (25g available carbohydrate of each) given as breakfast to fasting participants
Experimental: Pea variety 3 with potato
Group 2, Visit 2-5 Pea variety 3 with potato (25g available carbohydrate of each) given as breakfast to fasting participants
Experimental: Potato
Group2, Visit 2-5 Potato (equal to 50g available carbohydrate) given as breakfast to fasting participants

资格标准

有资格学习的年龄 18 Years 至 18 Years
有资格学习的性别All
接受健康志愿者
标准

Inclusion criteria

1. Generally healthy male or female, between the age of 18-40 years;

2. Body mass index (BMI) 18.5-34.5 kg/m2;

3. HbA1c <6.0%;

4. Willing to provide informed consent;

5. Willing/able to comply with the requirements of the study.

Exclusion criteria

1. Pregnant or lactating;

2. Medical history of diabetes mellitus, fasting plasma glucose ≥7.0 mmol/L or use of insulin or oral medication to control blood sugar;

3. Medical history of cardiovascular disease

4. Systolic blood pressure >140 mmHg or diastolic blood pressure >90 mmHg;

5. Fasting plasma total cholesterol >7.8 mmol/L;

6. Fasting plasma HDL <0.9 mmol/L;

7. Fasting plasma LDL >5.0 mmol/L;

8. Fasting plasma triglycerides >2.3 mmol/L;

9. A change in blood glucose concentration less than 1 mmol/L between baseline and 30 minutes after consumption of white bread at visit 1;

10. Maximum blood glucose concentration occurs after 60 minutes after consumption of white bread at visit 1;

11. Major surgery within the last 3 months;

12. Medical history of inflammatory disease (ie. Systemic lupus erythematosis, rheumatoid arthritis, psoriasis) or use of any corticosteroid medications within 3 months;

13. Medical history of liver disease or liver dysfunction (defined as plasma AST or ALT ≥1.5 times the upper limit of normal (ULN));

14. Medical history of kidney disease or kidney dysfunction (defined as blood urea nitrogen and creatinine ≥ 1.8 times the ULN));

15. Presence of a gastrointestinal disorder, daily use of any stomach acid-lowering medications or laxatives (including fibre supplements) within the past month or antibiotic use with the past 6 weeks;

16. Active treatment for any type of cancer within 1 year prior to study start;

17. Other medical, psychiatric, or behavioral factors that in the judgment of the principal Investigator may interfere with study participation or the ability to follow the intervention protocol;

18. Shift worker;

19. Tobacco use current or within the last 3 months;

20. Allergies to peas;

21. Aversion or unwillingness to eat study foods;

22. Consuming >4 servings of pulses per week;

23. Use of any prescription or non-prescription drug, herbal or nutritional supplement known to affect glycemia;

24. Participation in another clinical trial, current or in the past 4 weeks;

25. Unstable body weight (defined as >5% change in 3 months) or actively participating in a weight loss program.

结果

主要结果指标

1. Postprandial blood glucose [up to 2 hours following a meal]

samples collected to test glucose at fasting and at 15,30,45,60,90 and 120 minutes after the first bite of the test product

2. Postprandial blood insulin [up to 2 hours following a meal]

samples collected to test insulin at fasting and at 15,30,45,60,90 and 120 minutes after the first bite of the test product

次要成果指标

1. Hunger (Visual analogue scales) [up to 2 hours following a meal]

Visual analogue scales are administered pre-meal, immediately post-meal and 30, 60, 90 and 120 minutes

2. Fullness (Visual analogue scales) [up to 2 hours following a meal]

Visual analogue scales are administered pre-meal, immediately post-meal and 30, 60, 90 and 120 minutes

3. Desire to eat (Visual analogue scales) [up to 2 hours following a meal]

Visual analogue scales are administered pre-meal, immediately post-meal and 30, 60, 90 and 120 minutes

其他成果措施

1. Acceptability of test products based on sensory scales [immediately after eating test product]

scales will assess overall, colour, aroma, flavour and texture likeability

2. Gastrointestinal side effects [up to 24 hours following a meal]

After consumption of the test product, any abnormal gastrointestinal side effects will be recorded

加入我们的脸书专页

科学支持的最完整的草药数据库

  • 支持55种语言
  • 科学支持的草药疗法
  • 通过图像识别草药
  • 交互式GPS地图-在位置标记草药(即将推出)
  • 阅读与您的搜索相关的科学出版物
  • 通过药效搜索药草
  • 组织您的兴趣并及时了解新闻研究,临床试验和专利

输入症状或疾病,并阅读可能有用的草药,输入草药并查看所使用的疾病和症状。
*所有信息均基于已发表的科学研究

Google Play badgeApp Store badge